Motif Bio PLC (LON:MTFB)‘s stock had its “buy” rating reaffirmed by stock analysts at Northland Securities in a report released on Thursday.

Several other brokerages have also recently issued reports on MTFB. FinnCap dropped their target price on Motif Bio PLC from GBX 125 ($1.66) to GBX 100 ($1.33) and set a “buy” rating for the company in a report on Wednesday, June 7th. Beaufort Securities restated a “speculative buy” rating and issued a GBX 110 ($1.46) target price on shares of Motif Bio PLC in a report on Monday.

Motif Bio PLC (LON MTFB) opened at 44.50 on Thursday. The firm’s 50-day moving average is GBX 29.96 and its 200 day moving average is GBX 30.44. Motif Bio PLC has a 1-year low of GBX 21.44 and a 1-year high of GBX 53.50. The stock’s market capitalization is GBX 116.98 million.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at

Motif Bio PLC Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.